Hassan R - Search Results

1

Development of Highly Effective Anti-Mesothelin hYP218 Chimeric Antigen Receptor T Cells With Increased Tumor Infiltration and Persistence for Treating Solid Tumors.

Tomar S, Zhang J, Khanal M, Hong J, Venugopalan A, Jiang Q, Sengupta M, Miettinen M, Li N, Pastan I, Ho M, Hassan R. Tomar S, et al. Among authors: hassan r. Mol Cancer Ther. 2022 Jul 5;21(7):1195-1206. doi: 10.1158/1535-7163.MCT-22-0073. Mol Cancer Ther. 2022. PMID: 35499461 Free PMC article.

2

111Indium-labeled monoclonal antibody K1: biodistribution study in nude mice bearing a human carcinoma xenograft expressing mesothelin.

Hassan R, Wu C, Brechbiel MW, Margulies I, Kreitman RJ, Pastan I. Hassan R, et al. Int J Cancer. 1999 Feb 9;80(4):559-63. doi: 10.1002/(sici)1097-0215(19990209)80:4<559::aid-ijc13>3.0.co;2-y. Int J Cancer. 1999. PMID: 9935157

3

Anti-tumor activity of K1-LysPE38QQR, an immunotoxin targeting mesothelin, a cell-surface antigen overexpressed in ovarian cancer and malignant mesothelioma.

Hassan R, Viner JL, Wang QC, Margulies I, Kreitman RJ, Pastan I. Hassan R, et al. J Immunother. 2000 Jul-Aug;23(4):473-9. doi: 10.1097/00002371-200007000-00011. J Immunother. 2000. PMID: 10916757

4

Antitumor activity of SS(dsFv)PE38 and SS1(dsFv)PE38, recombinant antimesothelin immunotoxins against human gynecologic cancers grown in organotypic culture in vitro.

Hassan R, Lerner MR, Benbrook D, Lightfoot SA, Brackett DJ, Wang QC, Pastan I. Hassan R, et al. Clin Cancer Res. 2002 Nov;8(11):3520-6. Clin Cancer Res. 2002. PMID: 12429643

5

Pretreatment with rituximab does not inhibit the human immune response against the immunogenic protein LMB-1.

Hassan R, Williams-Gould J, Watson T, Pai-Scherf L, Pastan I. Hassan R, et al. Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):16-8. doi: 10.1158/1078-0432.ccr-1160-3. Clin Cancer Res. 2004. PMID: 14734446 Clinical Trial.

6

Mesothelin: a new target for immunotherapy.

Hassan R, Bera T, Pastan I. Hassan R, et al. Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):3937-42. doi: 10.1158/1078-0432.CCR-03-0801. Clin Cancer Res. 2004. PMID: 15217923 Review.

7

Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients.

Ho M, Hassan R, Zhang J, Wang QC, Onda M, Bera T, Pastan I. Ho M, et al. Among authors: hassan r. Clin Cancer Res. 2005 May 15;11(10):3814-20. doi: 10.1158/1078-0432.CCR-04-2304. Clin Cancer Res. 2005. PMID: 15897581

8

Pretargeted radioimmunotherapy of mesothelin-expressing cancer using a tetravalent single-chain Fv-streptavidin fusion protein.

Sato N, Hassan R, Axworthy DB, Wong KJ, Yu S, Theodore LJ, Lin Y, Park L, Brechbiel MW, Pastan I, Paik CH, Carrasquillo JA. Sato N, et al. Among authors: hassan r. J Nucl Med. 2005 Jul;46(7):1201-9. J Nucl Med. 2005. PMID: 16000290 Free article.

9

Localization of mesothelin in epithelial ovarian cancer.

Hassan R, Kreitman RJ, Pastan I, Willingham MC. Hassan R, et al. Appl Immunohistochem Mol Morphol. 2005 Sep;13(3):243-7. doi: 10.1097/01.pai.00000141545.36485.d6. Appl Immunohistochem Mol Morphol. 2005. PMID: 16082249

10

New monoclonal antibodies to mesothelin useful for immunohistochemistry, fluorescence-activated cell sorting, Western blotting, and ELISA.

Onda M, Willingham M, Nagata S, Bera TK, Beers R, Ho M, Hassan R, Kreitman RJ, Pastan I. Onda M, et al. Among authors: hassan r. Clin Cancer Res. 2005 Aug 15;11(16):5840-6. doi: 10.1158/1078-0432.CCR-05-0578. Clin Cancer Res. 2005. PMID: 16115924

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,179 results

Search Page

Filters